Don't qualify for this program? Visit the DBAs to look for financial assistance based on your diagnosis.  

AbbVie Patient Assistance Program Foundation for Norvir and Kaletra

This program provides brand name medications at no or low cost

Provided by: AbbVie

PO Box 270
Somerville, NJ 08876

TEL: 800-222-6885

FAX: 866-483-1305
Languages Spoken:


Program Website


Patient Assistance Applications

AbbVie Patient Assistance Foundation Application for Norvir and Kaletra

HIV Common Application: AbbVie (KALETRA, NORVIR)


Brand Name Medications Covered

  • Kaletra
  • Norvir

Generic Name

  • lopinavir/ritonavir
  • ritonavir

Eligibility Requirements   

Insurance Status Must have no prescription coverage for needed medication
Those with Part D Eligible? Considered on exception basis
Income Not disclosed
Diagnosis/Medical Criteria Not specified
US Residency Required? Yes


Obtaining Call or download
Receiving Faxed, mailed or downloaded from website
Returning Fax or mail
Doctor's Action Complete section and sign
Applicant's Action Complete section, sign, attach a copy of proof of income
Decision Communicated Patient and Doctor notified of acceptance
Decision Timeframe Within 2-3 days


Amount/Supply Up to 90 day supply
Sent To Doctor's office
Delivery Time Within 3-5 business days
Refill Process Patient or Doctor must contact company
Limit Not specified
Re-application New application yearly

Additional Information

Each medication has different requirements. Any patient who requires the medication and are in need should call the company. Eligibility determined on a case-by-case basis. Patients with prescription drug coverage may be eligible on exception basis.

Copay Program: Contact the Patient Access Program 1-800-441-4987

This Program participates in the CPAPA. This single common application allows uninsured HIV-positive individuals with low incomes to use one application to apply for multiple assistance programs.

IMPORTANT: Send completed CPAPA to the corresponding addresses listed for each company.

Updated January 03, 2018